Original assessment ยท live

JBHT: Hold + Reduce

Published 16 Sep 2026, 16:39 BST. This is the frozen version, not the current recommendation.

Target$217.03
Target date2027-09-15
Price known at publication$270.452026-09-11

Why this assessment was issued

Stored financial statements changed; the revised figures need checking. The model version changed. The published model version has been replaced. Record the new calculation basis even if the rating is unchanged. The central target is 19.8% below the price. The decline falls short of the 25% Sell requirement.

The central target is 19.8% below the price. The decline falls short of the 25% Sell requirement.

Supporting evidence

Year-to-date profit has improved

Across 2 completed quarters since 2025-12-31, net income was 322.6m versus 246.4m in the matching prior-year periods (USD). Check whether the latest quarter changes that direction.

More cash remains for each dollar of profit

Cash after capital spending / profit: 1.6ร— for JBHT, against 1.2ร— across 7 comparable peers.

Opposing evidence

Price has outpaced earnings

Over 1 year (2025-09-12 to 2026-09-11), price changed +96.1% and trailing EPS changed +28.4%. A wider gap changes the earnings multiple; it does not establish fair value.

The starting valuation is below the price

The central assumptions give $64.98 per share, -76.0% against the weekly close. This is a scenario to test, not an analyst price target.

The original scenarios

ScenarioSales growthProfit marginModel value
Weaker-2.9%4.9%$157.48
Central2.1%5.5%$217.03
Stronger7.1%6.1%$289.41

Method: Earnings and historical valuation. A sufficiently complete, positive earnings record allows the stock's own P/E history to be used. These scenarios are not probability intervals.

Original assumptions and checks
eps7.06
cash4162000.0
debt1145337000.0
years1.2101300479123889
growth2.0633262620512904
margin5.310515214572355
profit674505000.0
cash_okTrue
debt_okTrue
growths[-0.4978210145392792, -1.5803083447857635, 4.62447353864186, 19.367484455366668]
revenue12701310000.0
downside41.77037192671082
leverage0.6817205637161634
multiple28.991007194244606
free_cash1099722000.0
buy_hurdle17.67023754033525
volatility35.3404750806705
history_end2026-09-11
reward_risk0.0
annual_years5
usable_weeks157
history_start2023-09-15
history_weeks157
financial_date2026-06-30
interest_cover13.653384006515124
operating_cash1595293000.0
uncapped_growth2.0633262620512904
current_multiple38.30736543909349
projected_margin5.493550734971117
historical_margin5.6765862553698785

Recent price ยท Passed. Weekly close dated 2026-09-11.

Suitable business model ยท Passed. Value operating cash flow or comparable earnings; deduct debt and other ownership claims where appropriate.

Four quarters ยท Passed. Four quarters ending 2026-06-30.

Current financials ยท Passed. Statements through 2026-06-30; factor prices dated 2026-09-11.

Annual record ยท Passed. 5 consecutive annual profit margins, including loss years.

Comparable earnings history ยท Passed. P/E is usable in 157 of 157 weeks. At least 52 usable weeks and 70% coverage are required; excluding too many loss or missing weeks would bias the target.

Earnings and price dates ยท Passed. Earnings-release EPS $7.06, for four quarters ending 2026-06-30.

Price risk ยท Passed. Risk uses the latest 52 weekly price changes.

Comparable sales growth ยท Passed. Growth uses the median of four quarterly year-on-year comparisons.

Positive statement earnings ยท Passed. Trailing statement profit is positive.

Earnings reconciliation ยท Passed. Release EPS is $7.06; statement-derived EPS is $7.18. The difference is within the 5% review threshold; this does not prove there are no unusual items.

Statement totals ยท Passed. The latest four quarters agree with the trailing snapshot within 5%.

Cash and borrowing ยท Passed. Cash generation, debt and interest-cover figures are available.

Target publication review ยท Passed. The model estimate is within SM's automatic publication range of one quarter to four times the current price. This is a review threshold, not evidence that the market price is correct.

Policy sm-review-2-research ยท Model sm-assessment-14-operating-capital ยท Data 3e7981eea2be.

Open current research โ†—

Evidence context